AIM ImmunoTech (AIM) Cash from Operations (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Cash from Operations came in at 2719000.0 in Q1 2026, down 15.16% YoY from 3204972.04 in Q1 2025, and down 36.91% on a QoQ basis from 1986000.0 in Q4 2025.
AIM ImmunoTech (AIM) Cash from Operations (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Cash from Operations data on file, last reported at 2719000.0 in Q1 2026.
- Quarterly Cash from Operations fell 15.16% year-over-year to 2719000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11315000.0 (up 9.0% YoY) and the FY2025 annual result came in at 10957000.0, up 26.4% from the prior year.
- Cash from Operations slipped to 2719000.0 in Q1 2026, from 1986000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1531000.0 in Q2 2025 to a low of 9758000.0 in Q4 2023.
- A 5-year average of 3878764.71 and a median of 3110000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations jumped 59.47% — and 2025, when it slumped 63.31%.
- Tracing AIM's Cash from Operations over 5 years: stood at 6069000.0 in 2022, then slumped by 60.78% to 9758000.0 in 2023, then jumped by 59.47% to 3955000.0 in 2024, then soared by 49.79% to 1986000.0 in 2025, then plunged by 36.91% to 2719000.0 in 2026.
- The last three Cash from Operations figures came in at 2719000.0 (Q1 2026), 1986000.0 (Q4 2025), and 5079000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 728.46 Mn |
| 10 | AIM ImmunoTech | 4.42 Mn | -5.54 Mn | 21,000.00 | -4.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.59 Mn |
| Jun 30, 2026 | -4.59 Mn |
| Mar 31, 2026 | -2.72 Mn |
| Mar 31, 2026 | -2.72 Mn |
| Dec 31, 2025 | -1.99 Mn |
| Dec 31, 2025 | -1.99 Mn |
| Sep 30, 2025 | -5.08 Mn |
| Sep 30, 2025 | -5.08 Mn |
| Jun 30, 2025 | -1.53 Mn |
| Jun 30, 2025 | -1.53 Mn |
| Mar 31, 2025 | -2.36 Mn |
| Mar 31, 2025 | -2.36 Mn |
| Dec 31, 2024 | -3.96 Mn |
| Dec 31, 2024 | -3.96 Mn |
| Sep 30, 2024 | -3.11 Mn |
| Sep 30, 2024 | -3.11 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Mar 31, 2024 | -4.82 Mn |